Cargando…
Radiotherapy plus Concomitant Adjuvant Temozolomide for Glioblastoma: Japanese Mono-Institutional Results
This study was conducted to investigate the feasibility and survival benefits of combined treatment with radiotherapy and temozolomide (TMZ), which has been covered by the national health insurance in Japanese patients with glioblastoma since September 2006. Between September 2006 and December 2011,...
Autores principales: | Oike, Takahiro, Suzuki, Yoshiyuki, Sugawara, Ken-ichi, Shirai, Katsuyuki, Noda, Shin-ei, Tamaki, Tomoaki, Nagaishi, Masaya, Yokoo, Hideaki, Nakazato, Yoichi, Nakano, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3827088/ https://www.ncbi.nlm.nih.gov/pubmed/24265731 http://dx.doi.org/10.1371/journal.pone.0078943 |
Ejemplares similares
-
Slug, Twist, and E-Cadherin as Immunohistochemical Biomarkers in Meningeal Tumors
por: Nagaishi, Masaya, et al.
Publicado: (2012) -
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma—A Critical Review
por: Komotar, Ricardo J., et al.
Publicado: (2008) -
Trotabresib (CC-90010) in combination with adjuvant temozolomide or concomitant temozolomide plus radiotherapy in patients with newly diagnosed glioblastoma
por: Vieito, Maria, et al.
Publicado: (2022) -
Comparison of hematological toxicities between innovator and generic cisplatin formulations in cervical cancer patients treated with concurrent chemoradiotherapy
por: Oike, Takahiro, et al.
Publicado: (2013) -
Comparison of the radiosensitivities of neurons and glial cells derived from the same rat brain
por: KUDO, SHIGEHIRO, et al.
Publicado: (2014)